This insider cluster is too small to warrant a directional trade. Monitor for any upcoming earnings or pipeline catalysts (e.g., ZORYVE label expansion) that could drive the stock, but ignore this selling as noise.
Price Chart
Executive Summary
Three insiders at Arcutis Biotherapeutics sold a total of $198K in open-market sales over a 7-day window, with the largest sale ($124K) by Director Howard Welgus. The total value is only ~0.006% of the company's $3.2B market cap, making this a trivial cluster by proportionality. The sales are likely routine portfolio diversification or tax-related, not a bearish signal on the company's fundamentals, especially given the strong analyst consensus (86% bullish) and positive historical performance of prior reports on this ticker (83% win rate at T+20). No cross-filing context suggests distress or material negative news; the cluster is neutral and low-impact.
Key Financial Metrics
Key Facts
- Three insiders sold shares totaling $198K in open-market sales from Aug 13-20, 2026.
- Total sales represent only ~0.006% of Arcutis's $3.2B market cap, well below the 0.1% materiality threshold.
- Director Howard Welgus accounted for the largest sale at $124K; Director Terrie Curran also exercised non-cash derivatives.
- Analyst consensus is 86% bullish (12 Buy/2 Hold/0 Sell), and prior reports on ARQT have an 83% win rate at T+20.
- No cross-filing context indicates distress, earnings miss, or material negative news.
Financial Impact
Total insider sales of $198K, or ~0.006% of market cap — immaterial.
Risk Factors
- Insider sales could accelerate if insiders perceive the stock as fully valued near $26-27.
- No material risk from this cluster; the primary risk is the company's execution on its commercial-stage dermatology pipeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ARQT-1787615130398 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 24, 2026 5w ago | Insider Cluster | $24.86 $26.38 | ▲ +6.11% | ▲ +5.87% | $25.16 (+1.21%) |
Aug 21, 2026 6w ago | Insider Cluster | $25.08 $25.96 | ▲ +3.51% | ▲ +4.04% | $25.16 (+0.32%) |
Aug 19, 2026 6w ago | Insider Cluster | $25.35 $25.38 | ▲ +0.12% | ▲ +0.12% | $25.16 (−0.75%) |
Aug 11, 2026 7w ago | 144 | $26.28 $23.38 | ▼ −11.04% | ▼ −9.14% | $25.16 (−4.26%) |
Aug 6, 2026 8w ago | Insider Cluster | $26.43 $23.66 | ▼ −10.48% | ▼ −11.08% | $25.16 (−4.81%) |
Aug 5, 2026 8w ago | Press Release | $26.43 $23.66 | ▼ −10.48% | ▼ −11.08% | $25.16 (−4.81%) |
Aug 3, 2026 8w ago | 144 | $26.03 $23.75 | ▼ −8.76% | ▼ −7.52% | $25.16 (−3.34%) |
Jun 29, 2026 13w ago | Press Release | $26.22 $27.84 | ▲ +6.18% | ▲ +7.21% | $25.16 (−4.04%) |
Jun 18, 2026 15w ago | Insider Cluster | $26.21 $27.74 | ▲ +5.84% | ▲ +5.30% | $25.16 (−4.01%) |
Jun 9, 2026 16w ago | 8-K | $23.23 $28.78 | ▲ +23.89% | ▲ +20.27% | $25.16 (+8.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access